A special message from the Editor of Market Watch Post: We are often approached by other businesses with special offers for our readers. While many don’t make the cut, the message below is one we believe deserves your consideration.
Dear Fellow Investor, On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of genetic software that can "Cut & Paste" any disease from your body. This revolutionary new kind of treatment will not just change medicine - It has the potential to eliminate genetic disease from our species. If that sounds like science fiction, consider this - The Nobel Prize Committee is calling it "The Holy Grail of Medicine" The Wall Street Journal reports the company is "transforming medicine." 60 Minutes reports the company is "revolutionizing the search for new drugs." And the biggest drug companies have rushed to invest over a $1 billion in one year alone - Juno Pharma invested $700 million. Glaxo SmithKline invested $350 million. Johnson and Johnson invested $292 million. That's on top of the $120 million Bill Gates and Google Ventures already invested into this. The list goes on and on... Never before has so much money invested in a new treatment so quickly. And because of that, it's going to create more millionaires than any other single breakthrough in history. More than the internet, more than computers, more than cars. Investor's Business Daily estimates the market is worth at least $75 billion. But right now, its stock price is just a tiny fraction of that size. Our research proves that anyone who gets in today could make like-changing gains. That's if the company doesn't get taken over for fast 300% gains first. CLICK HERE to see how you can profit from this rare opportunity >>> "The Buck Stops Here,"
For any personalized assistance or questions, simply reply to this email for a swift resolution. Contact us at [email protected] for other concerns.
Ownership and operation of the Market Watch Post rest with Stark Media LLC.
